Changes in Mental and Physical Status and Potential Treatment for Patients with Post-COVID-19 Chronic Heart Failure
- Authors: Nurmakhanova Z.M.1, Zhankalova Z.M.1, Abdugulova G.Z.1, Abdykulova A.B.1, Gabdulina G.H.1, Tazhieva A.E.1, Khabizhanova V.B.1, Omarova I.S.1, Ensegenova Z.Z.1, Yerenchina E.R.1, Kasymova R.N.1, Matchanova M.S.1, Erlepessova A.T.1, Yessirkepova A.Z.1, Zhaparkulova M.T.1, Kushimbaeva K.S.1, Tuleutayeva S.A.1
-
Affiliations:
- Asfendiyarov Kazakh National Medical University
- Issue: Vol 29, No 2 (2025)
- Pages: 51-62
- Section: Original study article
- URL: https://journal-vniispk.ru/RFD/article/view/313555
- DOI: https://doi.org/10.17816/RFD640797
- EDN: https://elibrary.ru/SYIHXO
- ID: 313555
Cite item
Abstract
BACKGROUND: Coronavirus infection can negatively impact the mental and physical status of patients with chronic heart failure, exacerbating anxiety and depressive symptoms. These changes should be recognized and addressed promptly.
AIM: The study aimed to evaluate the impact of COVID-19 on the mental and physical status of patients with chronic heart failure who were eligible for treatment in primary care settings.
METHODS: The study included patients with chronic heart failure of various origins with or without a history of COVID-19. The physical and mental health of all patients was evaluated using three scales: the Sheehan Patient-Rated Anxiety Scale, the Beck Depression Inventory, and the Social Adaptation Self-Evaluation Scale. Eligible patients with COVID-19 were prescribed sertraline, a selective serotonin reuptake inhibitor antidepressant, based on results of a psychometric evaluation.
RESULTS: Sertraline is shown to significantly improve anxiety disorder, particularly severe cases, in patients with chronic heart failure who have recovered from COVID-19. Sertraline was found to be even more clinically effective in the treatment of depression; it improved depressive symptoms in all study groups. Sertraline was found to affect cardiovascular parameters in patients with chronic heart failure after COVID-19. Sertraline decreased heart rate, thereby improving the course of chronic heart failure. In addition, the ejection fraction remained virtually unchanged in the short term, which indicates the efficacy and safety of sertraline. This supports the recommendation to add sertraline to the combined therapy for this patient group.
CONCLUSION: The study confirms the significant impact of COVID-19 on the physical and mental status of patients with chronic heart failure. However, the agents used to treat these conditions may affect the cardiovascular system. Patients require a comprehensive treatment strategy that includes support for mental and physical health.
Full Text
##article.viewOnOriginalSite##About the authors
Zhannat M. Nurmakhanova
Asfendiyarov Kazakh National Medical University
Email: zhanna12932@mil.ru
ORCID iD: 0000-0002-6528-7060
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyZulfiya M. Zhankalova
Asfendiyarov Kazakh National Medical University
Email: zulfiya-zhankalo@mail.ru
ORCID iD: 0000-0002-5122-4130
MD, Dr. Sci. (Medicine)
Kazakhstan, AlmatyGulbanu Z. Abdugulova
Asfendiyarov Kazakh National Medical University
Email: a.gulbany@mail.ru
ORCID iD: 0000-0001-8832-9705
Kazakhstan, Almaty
Akmaral B. Abdykulova
Asfendiyarov Kazakh National Medical University
Email: akmaral_abd@mail.ru
ORCID iD: 0000-0002-0330-6764
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyGulzhan H. Gabdulina
Asfendiyarov Kazakh National Medical University
Email: gabdulina.g@kaznmu.kz
ORCID iD: 0000-0001-5536-6227
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyAigul E. Tazhieva
Asfendiyarov Kazakh National Medical University
Email: a.tazhiyeva@mail.ru
ORCID iD: 0000-0002-3674-0321
MD, Dr. Sci. (Medicine)
Kazakhstan, AlmatyVenera B. Khabizhanova
Asfendiyarov Kazakh National Medical University
Email: habizhanova.v@kaznmu.kz
ORCID iD: 0000-0002-7488-0173
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyIndira S. Omarova
Asfendiyarov Kazakh National Medical University
Email: indiraomarova.kz1989@gmail.com
ORCID iD: 0000-0001-8312-0558
Kazakhstan, Almaty
Zoya Zh. Ensegenova
Asfendiyarov Kazakh National Medical University
Email: zoyazhar@mail.ru
ORCID iD: 0009-0008-9934-9523
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyElmira R. Yerenchina
Asfendiyarov Kazakh National Medical University
Email: elmira_er@mail.ru
ORCID iD: 0000-0002-4318-2946
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyRaushan N. Kasymova
Asfendiyarov Kazakh National Medical University
Email: rau-nur@mail.ru
ORCID iD: 0000-0002-0845-9794
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyMarzhan S. Matchanova
Asfendiyarov Kazakh National Medical University
Email: maka130773@mail.ru
ORCID iD: 0009-0002-6979-899X
MD, Cand. Sci. (Medicine)
Kazakhstan, AlmatyAigul T. Erlepessova
Asfendiyarov Kazakh National Medical University
Email: aigul.a_84@mail.ru
ORCID iD: 0009-0009-6882-3605
Kazakhstan, Almaty
Aizhamal Zh. Yessirkepova
Asfendiyarov Kazakh National Medical University
Author for correspondence.
Email: aizhamal-65@mail.ru
ORCID iD: 0000-0003-2991-8651
Kazakhstan, Almaty
Madina T. Zhaparkulova
Asfendiyarov Kazakh National Medical University
Email: mediksun@mail.ru
ORCID iD: 0009-0009-7795-0657
Kazakhstan, Almaty
Kaldygul Sh. Kushimbaeva
Asfendiyarov Kazakh National Medical University
Email: kalda77@mail.ru
ORCID iD: 0009-0000-8994-710X
Kazakhstan, Almaty
Svetlana A. Tuleutayeva
Asfendiyarov Kazakh National Medical University
Email: maxataul@mail.ru
ORCID iD: 0000-0002-9287-0454
Kazakhstan, Almaty
References
- Chazova IE, Mironova OI. COVID-19 and cardiovascular disease. Therapeutic archive. 2020;92(9):4–7. EDN: FQHMYD doi: 10.26442 0403660.2020.09.000742
- Bubnova MG, Aronov DM. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya. 2020;30(5):688–699. EDN: MBFPGQ doi: 10.18093/0869-0189-2020-30-5-688-699
- Sergienko E. Psychological health. Subjective factors. RGGU bulletin. Series: psychology. Pedagogics. Education series. 2017;4(10):98–117. EDN: YUPFFS
- Kozlov IA, Tyurin IN. Cardiovascular complications of COVID-19. Messenger of anesthesiology and resuscitation. 2020;17(4):14–22. EDN: MKJCLI doi: 10.21292/2078-5658-2020-17-4-14-22
- Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):4–20. doi: 10.15829/1560-4071-2020-3-3801
- Kotov AM, Stotsky AD, Kolesnikov DB. Antidepressants in cardiology. Clinical medicine (Russian journal). 2012;90(10):11–16. EDN: PULMCJ
- Barbarash OL, Karetnikova VN, Kashtalap VV, et al. New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2020;9(2):17–28. EDN: LJIYBE doi: 10.17802/2306-1278-2020-9-2-17-28
- Gromova OA, Torshin IYu, Gabdulina GKh. COVID-19 pandemic: protective role of vitamin D. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(2):132–145. EDN: IEDAKT doi: 10.17749/2070-4909/farmakoekonomika.2020.044
- Polonskaya YaV, Kashtanova EV, Stakhneva EM, et al. COVID-19 and cardiovascular diseases. Ateroscleroz. 2020;16(2):73–79. doi: 10.15372/ATER20200207
- mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP), version 2.0 [Internet]. Available from: https://www.who.int/europe/ru/publications/i/item/9789241549790. Accessed: 21 May 2025.
- The course of CHF in patients who have had COVID-19 [Internet]. Eurasian Association of Therapists. 2020. Available from: https://euat.ru/publications/techenie_hsn_u_patsientov_perenesshih_ covid_19. Accessed: 21 May 2025.
- Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232. doi: 10.1007/s00059-020-04909-z
- Elkind MS, Harrington RA, Benjamin IJ. Role of the American Heart Association in the global COVID-19 pandemic. Circulation. 2020;141(15):e743–e745. doi: 10.1161/Circulationaha.120.046749
- Petrova NN. Comorbid psychiatric disorders as an efficiency factor of treatment and rehabilitation of cardiac patients. Bulletin of the east Siberian scientific center SB RAMS. 2016;1(6(112)):88–91. EDN: XDMPHT
- Nurmakhanova Zh, Zhankalova Z, Abdugulova G, et al. Impact of coronavirus infection on the psychosomatic state of patients with chronic cardiac insufficiency. Phthisiopulmonology. 2024.(4):55–67. EDN: ERHUQU doi: 10.26212/2227-1937.2025.59.52.008
- Shcherbatykh YuV. Comparative assessment of methods for diagnosing anxiety. Bulletin on pedagogics and psychology of Southern Siberia. 2021;(2):85–104. EDN: THZFUA doi: 10.24412/2303-9744-2021-2-85-104
- Yelshansky SP, Anufriev AF, Efimova OS, Semyonov DV. Retest reliability of the A. Beck scale of depression features. Psychology, sociology and pedagogy. 2016;(4(55)):91–95. EDN: WCKNGV
- Roshchina OV, Simutkin GG, Bokhan NA, Surovtseva AK. Social adaptation level and its relationship with the main clinico-dynamic and psychological characteristics in the comorbidity of affective disorders and alcohol dependence. Neurology, neuropsychiatry, Psychosomatics. 2022;14(3):32–37. EDN: VMNHCX doi: 10.14412/2074-2711-2022-3-32-37
- Karaseva AA, Khudiakova AD, Garbuzova EV, et al. Severity of postcovid syndrome: a systematic review. The Russian Archives of Internal Medicine. 2024;13(6):422–435. doi: 10.20514/2226-6704-2023-13-6-422-435
- Zuin M, Rigatelli G, Roncon L, et al. Risk of incident heart failure after COVID-19 recovery: a systematic review and meta-analysis. Heart Fail Rev. 2023;28(4):859–864. doi: 10.1007/s10741-022-10292-0
- Luo M, Guo L, Yu M, et al. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public: a systematic review and meta-analysis. Psychiatry Res. 2020;291:113190. doi: 10.1016/j.psychres.2020.113190
Supplementary files
